)
)
Ironwood Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Ironwood Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Ironwood Pharmaceuticals Inc
Access all reports
Ironwood Pharmaceuticals, Inc., is a healthcare company that focuses on the development and commercialization of gastrointestinal products. The company develops linaclotide, a guanylate cyclase type-C agonist for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation under the LINZESS name in the United States and under the CONSTELLA name in Europe; and lesinurad for gout.
Key slides for Ironwood Pharmaceuticals Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Ironwood Pharmaceuticals Inc
Q3 2024
Ironwood Pharmaceuticals Inc
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
IRWD
Country
🇺🇸 United States